Avancerad sökning
Visar resultat 1 - 5 av 1476 avhandlingar som matchar ovanstående sökkriterier.
1. Inhibitors Targeting Insulin-Regulated Aminopeptidase (IRAP) : Identification, Synthesis and Evaluation
Sammanfattning : Insulin-regulated aminopeptidase (IRAP) has emerged as a potential new therapeutic target for treatment of cognitive disorders. Inhibition of the enzymatic activity facilitates cognition in rodents. LÄS MER
2. Design and Synthesis of Galectin Inhibitors
Sammanfattning : Galectins, a lectin family, have shown binding affinities towards b-galactosides. Galectins have been proposed to be involved in a wide range of functions like for example, cell growth, adhesion, migration, chemo taxis and apoptosis. They have also been associated with various cancer types. LÄS MER
3. Ethanol from lignocellulose : physiological effects of inhibitors and fermentation strategies
Sammanfattning : Fermentative ethanol production from dilute-acid hydrolyzates of wood using the yeast Saccharomyces cerevisiae was investigated. Of known inhibitors in hydrolyzates, acetic acid, furfural and hydroxymethyl furfural (HMF) were found in the highest concentrations (up to about 10 g/l). LÄS MER
4. Galectin Inhibitors – Molecular Tools in Biomedical Research and Clinical Implications
Sammanfattning : Galectins are β-galactoside-binding lectins, which are present in both the intracellular and extracellular environments of cells. During the last two decades, galectins have gained increasing interest as drug targets in various diseases, such as chronic inflammation (fibrosis) and cancer, in which galectins have been shown to play important, and sometimes rate-limiting, roles. LÄS MER
5. Peptidomimetic Enzyme Inhibitors : Targeting M. tuberculosis Ribonucleotide Reductase and Hepatitis C Virus NS3 Protease
Sammanfattning : This thesis focuses on the design and synthesis of inhibitors targeting Mycobacterium tuberculosis ribonucleotide reductase (RNR) and hepatitis C virus (HCV) NS3 protease; enzymes that have been identified as potential drug targets for the treatment of tuberculosis and hepatitis C, respectively. Small peptides have been recognized as inhibitors of these enzymes. LÄS MER